Bones are everybody’s business. This means that clinical osteology, now an independent specialty, nevertheless encompasses all branches of medicine and affects each and every one of us. Intended for doctors who seek precise information on bisphosphonates in medical practice, this book has been designed as an up-to-date manual to deal with the currently recognized indications for bisphosphonates, to outline situations and conditions for prevention of skeletal disorders, and to provide practical guidelines for treatment.
Bones are everybody’s business. This means that clinical osteology, now an independent specialty, nevertheless encompasses all branches of medicine and affects each and every one of us. Intended for doctors who seek precise information on bisphosphonates in medical practice, this book has been designed as an up-to-date manual to deal with the currently recognized indications for bisphosphonates, to outline situations and conditions for prevention of skeletal disorders, and to provide practical guidelines for treatment.
A concise review of the current knowledge of osteoporosis, aimed at the busy pratitioner who is increasingly involved in the management of osteoporosis and who wants accurate and practical answers to questions that arise in daily clinical practice. All the major aspects are covered including diagnosis, fractures, prevention and treatment. Each chapter has been written by a recognised expert in the field to provide readers with the most up-to-date and authoritative knowledge on each of the topics discussed, making this an invaluable source of reference.
"This volume presents manuscripts stemming from the conference entitled 'Bisphosphonates & Osteonecrosis of the Jaw,' held May 19, 2007 at the New York Academy of Sciences
Since the publication of the first edition, the U.S. Surgeon General released the first-ever report on bone health and osteoporosis in October 2004. This report focuses even more attention on the devastating impact osteoporosis has on millions of lives. According to the National Osteoporosis Foundation, 2 million American men have osteoporosis, and another 12 million are at risk for this disease. Yet despite the large number of men affected, the lack of awareness by doctors and their patients puts men at a higher risk that the condition may go undiagnosed and untreated. It is estimated that one-fifth to one-third of all hip fractures occur in men. This second edition brings on board John Bilezikian and Dirk Vanderschueren as editors with Eric Orwoll. The table of contents is more than doubling with 58 planned chapters. The format is larger – 8.5 x 11. This edition of Osteoporosis in Men brings together even more eminent investigators and clinicians to interpret developments in this growing field, and describe state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy. - Brings together more eminent investigators and clinicians to interpret developments in this growing field - Describes state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy - There is no book on the market that covers osteoporosis in men as comprehensively as this book
This first-ever Surgeon General's Report on bone health and osteoporosis illustrates the large burden that bone disease places on our Nation and its citizens. Like other chronic diseases that disproportionately affect the elderly, the prevalence of bone disease and fractures is projected to increase markedly as the population ages. If these predictions come true, bone disease and fractures will have a tremendous negative impact on the future well-being of Americans. But as this report makes clear, they need not come true: by working together we can change the picture of aging in America. Osteoporosis, fractures, and other chronic diseases no longer should be thought of as an inevitable part of growing old. By focusing on prevention and lifestyle changes, including physical activity and nutrition, as well as early diagnosis and appropriate treatment, Americans can avoid much of the damaging impact of bone disease and other chronic diseases. This Surgeon General's Report brings together for the first time the scientific evidence related to the prevention, assessment, diagnosis, and treatment of bone disease. More importantly, it provides a framework for moving forward. The report will be another effective tool in educating Americans about how they can promote bone health throughout their lives. This first-ever Surgeon General's Report on bone health and osteoporosis provides much needed information on bone health, an often overlooked aspect of physical health. This report follows in the tradition of previous Surgeon Generals' reports by identifying the relevant scientific data, rigorously evaluating and summarizing the evidence, and determining conclusions.
Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.
This book is an essential handbook on bisphosphonates, the most widely used new class of drugs for osteoporosis therapy. It reviews basic physiology in addition to the indications and adverse reactions of these drugs. Bisphosphonates in Bone Disease, 4E, discusses the compounds' chemistry, mechanisms of action, and animal toxicology before presenting a clinical picture of the diseases treated by bisphosphonates. The book provides a table listing the trade names of the commercially available bisphosphonates, registered indications, and the available forms for various countries. The revised Fourth Edition contains approximately 50% new material, including information on all of the latest drugs. * The revised fourth edition contains approximately 50% new material * Includes information on all the latest drugs
Marcus and Feldman's Osteoporosis, Fifth Edition, is the most comprehensive, authoritative reference on this disease. Led by a new editorial team, this fifth edition offers critical information on reproductive and hormonal risk factors, new therapeutics, ethnicity, nutrition, therapeutics, management and economics, comprising a tremendous wealth of knowledge in a single source not found elsewhere. Written by renowned experts in the field, this two-volume reference is a must-have for biomedical researchers, research clinicians, fellows, academic and medical libraries, and any company involved in osteoporosis drug research and development. - Summarizes the latest research in bone biology and translational applications in a range of new therapeutic agents, including essential updates on therapeutic uses of calcium, vitamin D, SERMS, bisphosphonates, parathyroid hormone, and new therapeutic agents - Recognizes the critical importance of new signaling pathways for bone health, including Wnt, OPG and RANK, of interest to both researchers who study bone biology and clinicians who treat osteoporosis - Offers new insights into osteoporosis associated with menopause, pre-menopause, chronic kidney disease, diabetes, HIV and other immune disorders
